Literature DB >> 17056292

Bone mineral density in Marfan syndrome. A large case-control study.

Bertrand Moura1, Florence Tubach, Moana Sulpice, Catherine Boileau, Guillaume Jondeau, Christine Muti, Bertrand Chevallier, Yasmine Ounnoughene, Jean-Marie Le Parc.   

Abstract

OBJECTIVE: To measure bone mineral density (BMD) in a group of patients meeting Gand criteria for Marfan syndrome, comparatively with a group of healthy controls.
METHODS: Dual-energy X-ray absorptiometry (DEXA) was used to measure BMD at the hip and wrist in 130 patients seen at the Multidisciplinary Marfan Clinic, Paris, France. Results were compared to values in the database of the absorptiometry machine (Hologic QDR100) and to values in 72 healthy height-matched controls including 35 whose body mass index (BMI) values were similar to those in the patients.
RESULTS: A history of fractures was noted in 32 (24.6%) patients. Z-score values were significantly decreased in the patients compared to the Hologic database values at the femoral neck (-1.190+/-0.098, P<0.0001) and wrist (-1.403+/-1.06; P < 0.001). Patients had significantly lower BMD values at the femoral neck compared to the height-matched controls (0.841+/-0.15 versus 1.010+/-0.017; P<0.0001). BMD values were also significantly lower in the patients compared to the controls of similar height and BMI. BMD values did not correlate with history of fractures or acetabular protrusion. In the patients, BMD values lower than -2.5 correlated with presence of dural ectasia.
CONCLUSION: Men and women with Marfan syndrome have significant osteopenia independent from BMI.

Entities:  

Mesh:

Year:  2006        PMID: 17056292     DOI: 10.1016/j.jbspin.2006.01.026

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN: 1297-319X            Impact factor:   4.929


  17 in total

1.  Differential effects of alendronate and losartan therapy on osteopenia and aortic aneurysm in mice with severe Marfan syndrome.

Authors:  Harikiran Nistala; Sui Lee-Arteaga; Luca Carta; Jason R Cook; Silvia Smaldone; Gabriella Siciliano; Aaron N Rifkin; Harry C Dietz; Daniel B Rifkin; Francesco Ramirez
Journal:  Hum Mol Genet       Date:  2010-09-24       Impact factor: 6.150

2.  Power of deep, all-exon resequencing for discovery of human trait genes.

Authors:  Gregory V Kryukov; Alexander Shpunt; John A Stamatoyannopoulos; Shamil R Sunyaev
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-06       Impact factor: 11.205

Review 3.  When Low Bone Mineral Density and Fractures Is Not Osteoporosis.

Authors:  Smita Jha; Marquis Chapman; Kelly Roszko
Journal:  Curr Osteoporos Rep       Date:  2019-10       Impact factor: 5.096

4.  Skeletogenic phenotype of human Marfan embryonic stem cells faithfully phenocopied by patient-specific induced-pluripotent stem cells.

Authors:  Natalina Quarto; Brian Leonard; Shuli Li; Melanie Marchand; Erica Anderson; Barry Behr; Uta Francke; Renee Reijo-Pera; Eric Chiao; Michael T Longaker
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-16       Impact factor: 11.205

5.  Losartan increases bone mass and accelerates chondrocyte hypertrophy in developing skeleton.

Authors:  Shan Chen; Monica Grover; Tarek Sibai; Jennifer Black; Nahid Rianon; Abbhirami Rajagopal; Elda Munivez; Terry Bertin; Brian Dawson; Yuqing Chen; Ming-Ming Jiang; Brendan Lee; Tao Yang; Yangjin Bae
Journal:  Mol Genet Metab       Date:  2015-02-27       Impact factor: 4.797

6.  Hyperactive transforming growth factor-β1 signaling potentiates skeletal defects in a neurofibromatosis type 1 mouse model.

Authors:  Steven D Rhodes; Xiaohua Wu; Yongzheng He; Shi Chen; Hao Yang; Karl W Staser; Jiapeng Wang; Ping Zhang; Chang Jiang; Hiroki Yokota; Ruizhi Dong; Xianghong Peng; Xianlin Yang; Sreemala Murthy; Mohamad Azhar; Khalid S Mohammad; Mingjiang Xu; Theresa A Guise; Feng-Chun Yang
Journal:  J Bone Miner Res       Date:  2013-12       Impact factor: 6.741

7.  Fibrillin-1 directly regulates osteoclast formation and function by a dual mechanism.

Authors:  Kerstin Tiedemann; Iris Boraschi-Diaz; Irina Rajakumar; Jasvir Kaur; Peter Roughley; Dieter P Reinhardt; Svetlana V Komarova
Journal:  J Cell Sci       Date:  2013-09-15       Impact factor: 5.285

8.  Long-term clinical outcome and carrier phenotype in autosomal recessive hypophosphatemia caused by a novel DMP1 mutation.

Authors:  Outi Mäkitie; Renata C Pereira; Ilkka Kaitila; Serap Turan; Murat Bastepe; Tero Laine; Heikki Kröger; William G Cole; Harald Jüppner
Journal:  J Bone Miner Res       Date:  2010-10       Impact factor: 6.741

Review 9.  Perspectives on the revised Ghent criteria for the diagnosis of Marfan syndrome.

Authors:  Yskert von Kodolitsch; Julie De Backer; Helke Schüler; Peter Bannas; Cyrus Behzadi; Alexander M Bernhardt; Mathias Hillebrand; Bettina Fuisting; Sara Sheikhzadeh; Meike Rybczynski; Tilo Kölbel; Klaus Püschel; Stefan Blankenberg; Peter N Robinson
Journal:  Appl Clin Genet       Date:  2015-06-16

10.  Assessment of bone mineral status in children with Marfan syndrome.

Authors:  Monica Grover; Nicola Brunetti-Pierri; John Belmont; Kelly Phan; Alyssa Tran; Roman J Shypailo; Kenneth J Ellis; Brendan H Lee
Journal:  Am J Med Genet A       Date:  2012-08-07       Impact factor: 2.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.